Converge Bio Secures $25M Series A to Accelerate AI-Driven Drug Discovery Platform
核心洞察
Converge Bio (搜索) raised $25 million in Series A funding led by Bessemer Venture Partners (搜索) to expand its generative AI platform for drug discovery and development.
The company has completed over 40 programs with pharmaceutical and biotech partners, achieving single-digit nanomolar antibody binding affinities and 4-7x improvements in protein manufacturing yields.
Converge's platform integrates multiple proprietary AI models into end-to-end systems for target discovery, antibody design, and protein optimization across oncology (搜索), neurodegenerative, and autoimmune diseases (搜索).
Converge Bio (搜索) announced the completion of a $25 million Series A funding round led by Bessemer Venture Partners (搜索), bringing the Boston- and Tel Aviv-based AI drug discovery company's total funding to $30 million. The highly oversubscribed round, which closed 18 months after the company's founding, included participation from TLV Partners (搜索), Vintage Investment Partners (搜索), Saras Capital (搜索), and executives from Meta (搜索), OpenAI (搜索), and Wiz.
The funding comes as the AI drug discovery sector experiences unprecedented momentum, with billions in venture capital flowing into the space following Google (搜索)'s AlphaFold developers winning the Nobel Prize in Chemistry. Recent industry milestones include Eli Lilly's partnership with Nvidia (搜索) to build the pharmaceutical industry's most powerful AI supercomputer for drug discovery and Eli Lilly becoming the first pharma company to reach a $1 trillion market cap.
Bridging the AI Promise-Reality Gap
Despite the sector's momentum, Converge Bio (搜索) CEO and co-founder Dov Gertz identified a significant gap between AI promise and reality in drug discovery. "The conversation needs to shift from models to AI systems," Gertz said. "Unlike ChatGPT, you can't simply prompt a model and get useful results. There's a long road from a model that performs well on benchmarks to an AI system a biologist can actually use."
Gertz emphasized that effective AI drug discovery requires "high-quality data, the right architectures for the domain, and a tight experimental validation loop," explaining why "the vast majority of drug development is still done the old way: through trial and error, taking years and costing hundreds of millions of dollars."
Integrated AI Platform Delivers Results
Converge's platform combines multiple proprietary models into an end-to-end system that integrates directly into existing drug development workflows. The company has developed three discrete AI systems: antibody design, protein yield optimization, and biomarker and target discovery.
The antibody design system exemplifies Converge's integrated approach, incorporating three components: a generative model that creates novel antibodies (搜索), predictive models that filter antibodies based on molecular properties, and a physics-based docking system that simulates three-dimensional interactions between antibodies and targets.
Biologists can access actionable outputs including novel drug targets, optimized antibody candidates, and protein sequences optimized for increased yield without requiring coding skills or infrastructure development. The platform's models are experimentally validated and trained on Converge's large-scale datasets obtained through high-throughput screening, data acquisition, and rigorous curation of public data.
Commercial Traction Across Therapeutic Areas
The company has demonstrated strong commercial traction, completing over 40 programs with more than a dozen pharmaceutical and biotech customers across multiple therapeutic areas, including oncology (搜索), neurodegenerative, and autoimmune diseases (搜索). Converge's partnerships have yielded significant results: discovery of novel antibodies (搜索) with single-digit nanomolar binding affinities, consistent 4-7x improvements in protein manufacturing yields, and identification of novel molecular biomarkers to optimize patient response.
The startup has scaled rapidly, growing from nine employees in November 2024 to 34 employees currently, with operations spanning the U.S., Canada, Europe, and Israel, and expansion planned into Asia.
Addressing AI Challenges in Drug Discovery
Converge addresses key challenges in applying AI to drug discovery, particularly the issue of hallucinations in large language models. "In text, hallucinations are usually easy to spot," Gertz explained. "In molecules, validating a novel compound can take weeks, so the cost is much higher." The company mitigates this risk by pairing generative models with predictive ones to filter new molecules.
Regarding the use of text-based models, Gertz clarified that Converge doesn't rely on them for core scientific understanding. "To truly understand biology, models need to be trained on DNA (搜索), RNA (搜索), proteins (搜索), and small molecules," he said. Text-based LLMs serve only as support tools, such as helping customers navigate literature on generated molecules.
Industry Vision and Investment Perspective
"The AI drug discovery revolution is here," Gertz stated. "Our goal is simple: make every biotech and pharma company an AI company. We make it easy for scientists to identify where AI can deliver real results for them today, and provide them with our validated tools to get there."
Andrew Hedin, Partner at Bessemer Venture Partners (搜索), highlighted Converge's unique position in the competitive landscape. "Converge has something rare in this space: real commercial traction and strong scientific results," Hedin said. "The team has built validated solutions that are already delivering results for paying customers. As one of the most results-driven players in the field, we believe Converge is well positioned to be the de facto generative AI lab for the life sciences industry."
Leadership and Technical Expertise
Converge Bio (搜索)'s 40-person team brings deep expertise across machine learning, computational biology, and drug development, with approximately half holding advanced degrees in related fields. CEO Dov Gertz developed a machine-learning method for discovering novel CRISPR (搜索) systems, resulting in a U.S.-licensed patent and scientific publication in collaboration with Nobel laureate Jennifer Doudna. CSO Iddo Weiner holds a PhD in Bioinformatics and Biomedical Engineering and has led two drug programs through positive Phase 2 clinical readouts. CTO Oded Kalev previously led cybersecurity AI teams and has advised U.S. government agencies on large-scale generative AI applications.